SCHEMBL1662301

SCHEMBL1662301

N#Cc1cccc(C(=O)O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
HPGD P15428 2/20 0.52
ALB P02768 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MMP2 P08253 1/20 0.52
CXCR2 P25025 2/20 0.49
HNF4A P41235 1/20 0.48
HMGB1 P09429 2/20 0.44
ALOX15 P16050 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA9 Q16790 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11113016 0.82 CXCR2 (0.44) ALDH1A1KDM4ECXCR2SMN1; SMN2NOTUM
SCHEMBL7178852 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDALBHSD17B10
SCHEMBL180853 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHMGB1ALOX15
SCHEMBL29365220 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHMGB1ALOX15
SCHEMBL4851536 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDALBHSD17B10
SCHEMBL27869030 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDALBHSD17B10
SCHEMBL6908405 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHMGB1ALOX15
SCHEMBL6914996 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10HMGB1
SCHEMBL6913178 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHMGB1ALOX15
SCHEMBL6913805 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHMGB1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
CN-105886565-A Method for producing cyano hydroxyl benzoic acid from microorganisms 青岛科技大学 2016-08-24 CN disclosed
CN-105886565-A Method for producing cyano hydroxyl benzoic acid from microorganisms 青岛科技大学 2016-08-24 CN disclosed
EP-1871844-B1 BUBBLE COMPOSITION WITH COLOR CHANGING INDICATOR C2C TECHNOLOGIES LLC (US) 2014-08-27 EP disclosed
US-8703750-B2 Mixtures and methods for the induction of resistance in plants ISAGRO S.P.A. (IT) 2014-04-22 US disclosed
EP-1958940-B1 CONDENSATION REACTION BY METAL CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2013-06-26 EP disclosed
US-20110098479-A1 CONDENSATION REACTION BY METAL CATALYST MASHIMA KAZUSHI 2011-04-28 US disclosed
US-7888513-B2 Condensation reaction by metal catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-02-15 US disclosed
US-20100317519-A1 Mixtures and methods for the induction of resistance in plants ISAGRO S.P.A. (IT) 2010-12-16 US disclosed
WO-2005094580-A1 MIXTURES AND METHODS FOR THE INDUCTION OF RESISTANCE IN PLANTS ISAGRO S.P.A. (IT) 2005-10-13 WO disclosed
US-20050192318-A1 Compounds ASTRAZENECA AB (SE) 2005-09-01 US disclosed
US-6924277-B2 Cyclized benzamide neurokinin antagonists for use in therapy ASTRAZENECA AB (SE) 2005-08-02 US disclosed
US-20040029850-A1 Cyclized benzamide neurokinin antagonists for use in therapy ASTRA ZENECA AB (SE) 2004-02-12 US disclosed
EP-1324992-A1 CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY AstraZeneca AB (SE) 2003-07-09 EP disclosed
WO-2002026724-A1 CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY ASTRAZENECA AB (SE) 2002-04-04 WO disclosed
US-6251882-B1 TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR PARKER HUGHES INSTITUTE 2001-06-26 US disclosed
EP-1091934-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS Parker Hughes Institute (US) 2001-04-18 EP disclosed
WO-2000000469-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS PARKER HUGHES INSTITUTE (US) 2000-01-06 WO disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM ALDH1A1 1316/4885KDM4E 3650/4885HPGD 583/4885
US-20110098479-A1 CONDENSATION REACTION BY METAL CATALYST C9, CBR3, C1R ALDH1A1 2265/4885KDM4E 1848/4885HPGD 4312/4885
US-20100317519-A1 Mixtures and methods for the induction of resistance in plants SLC11A2, MYD88, ME2 ALDH1A1 2944/4885KDM4E 4408/4885HPGD 90/4885
US-20050192318-A1 Compounds PCSK9, CYP11B2, CYP27A1 ALDH1A1 1381/4885KDM4E 4125/4885HPGD 419/4885
US-20040029850-A1 Cyclized benzamide neurokinin antagonists for use in therapy BDKRB1, BDKRB2, NPY1R ALDH1A1 2186/4885KDM4E 3742/4885HPGD 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.